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Interventions for preventing injuries caused by impaired alertness in individuals with jet lag and shift work disorder (Protocol)
Injuries to patients arising from medical errors are an important cause of avoidable mortality and morbidity, and are a great concern for clinicians, hospital managers and the public. In the UK, it is estimated that there are in excess of 850,000 incidents (constituting approximately 10% of admissions) which either harm or nearly harm a NHS patient every year, incurring £2 billion direct costs in additional hospital days alone (DoH 2000) . In the USA, an estimated 44,000 to 98,000 deaths every year are caused by medical errors. Even when using the lowest estimate, this makes medical errors the eighth leading cause of death, exceeding the death toll from motor vehicle crashes, breast cancer and AIDS (Kohn 1999) . It is not just a concern for developed countries; in developing countries medical errors are likely to be more frequent than in the developed world, due to poor infrastructure, inadequate equipment, and other factors associated with severe underfinancing of health services (WHPA 2002) . There are numerous risk factors that can contribute to the occurrence of medical errors although the sleepiness of healthcare providers has been identified as being of concern (Gaba 2002; Jha 2001; Kohn 1999) , and there is evidence of an association between medical errors and sleep deprivation (Eastridge 2003; Weinger 2002) . Clinicians are required to have good attention, good judgment and quick reaction times, sometimes in high pressurised, emergency situations, all of which can be compromised by sleepiness (Jha 2001) . The impairment of alertness associated with sleepiness, leads to a deterioration of performance, attention and motivation, diminishment of mental concentration and intellectual capacity (WHO 2004) . A meta-analysis by Pilcher 1996, showed that the performance of sleep-deprived individuals was 
Circadian rhythm sleep disorders
Circadian rhythm sleep disorders (CRSDs) explain some of the sleepiness and associated impaired alertness that is prevalent in the population. The circadian rhythm describes the cyclical changes involving body temperature, hormone levels and sleep occurring over a 24 hour period, which are driven by our biological clock. This cycle is synchronised by rhythmic environmental cues, known as zeitgebers -the main zeitgebers are known to be the environmental light-dark cycle and the secretion of melatonin, both of which can be manipulated to induce a phase shift in an individual's circadian rhythm (Waterhouse 2007) . The circadian rhythm dictates the times at which we feel the typical urge to sleep at night and wake in the morning. CRSDs occur when there is a misalignment between a person's sleep pattern and the sleep pattern desired (AASM 2001), which results in symptoms of sleepiness and insomnia. Time zone change syndrome (i.e. jet lag) and shift work disorder (SWD) are two types of CRSD which can impair performance of workers in the health care and transportation industry, and are the focus of this review. These disorders can be considered distinct from the other CRSDs as sufferers of these conditions have circadian systems which function normally under usual circumstances (Sack 2007), which differs from the other disorders in which sufferers have an inherent problem with their circadian rhythm.
Time zone change syndrome (jet lag)
The American Academy of Sleep Medicine (AASM) describes jet lag as consisting "of varying degrees of difficulties in initiating or maintaining sleep, excessive sleepiness, decrements in subjective daytime alertness and performance, and somatic symptoms…following rapid travel across multiple timezones" (AASM 2001). Jet lag results from the misalignment between the circadian rhythm and the sleep-wake schedule in the new time zone. The severity of the symptoms of the disorder depend on the age of the traveller (severity increases with age), number of time zones crossed, direction of travel (eastward journeys are associated with more profound effects), time of travel and the individual's susceptibility (Waterhouse 2007 
Description of the intervention
Adequate, quality natural sleep is by far the most effective and safe measure for preventing the detrimental effects of lack of sleep, including injury. However, there will always be a need for individuals to sleep and/or be alert at times which are different to those dictated by their circadian rhythm. Consequently there is a need for interventions which can safely alleviate the impairment of alertness associated jet lag and SWD. Effective interventions to prevent and treat the jet lag and SWD have the potential to reduce the number of errors resulting from impaired alertness, thus preventing the occurrence of injury to themselves, and to others, that may result. Some interventions may aim to address the adverse effect on alertness arising from jet lag and SWD in two related, but distinct, ways. First, there are those interventions which aim to promote alertness during times of desired wakefulness (e.g. pharmacological stimulants) and those which aim to treat the insomnia symptom, and facilitate sleep during the desired times (e.g. pharmacological sedatives). Second, interventions may be employed to directly help the circadian rhythm to adjust to the new sleep-wake schedule (e.g. administration of bright light). A final type of intervention that might be employed are those which do not aim to treat an individual's symptoms, instead they attempt to directly prevent the occurrence of an error (e.g. alarm systems). In this systematic review we plan to review the evidence for the effects of all of the above types of interventions for use by those with jet lag or SWD.
Why it is important to do this review
As described above, the impaired alertness associated with the symptoms of jet lag and SWD is an important cause of injury and constitutes a significant threat to public safety. The main focus of this review is on the prevention of medical errors and identification of effective interventions of relevance to the health care industry. However, the scope of the review will be broadened to include evidence from all sectors for a number of reasons. First, there is a dearth of quality intervention research data about ways to reduce medical errors and improve patient safety (Ioannidis 2001), yet other fields such as aviation and road safety have a more developed research tradition in prioritising public safety and risk management. There is, therefore, much potential for the development of strategies aimed at preventing medical errors to be informed by research from other industries. Second, the issue of impaired alertness resulting from jet lag and SWD is not a concern of just one sector, rather it has far-reaching implications. By reviewing all relevant evidence this review will be able to serve as a resource for all sectors, not solely health care, which seek to address the burden of injuries resulting from impaired alertness. This broad perspective also accounts for the inclusion of jet lag, which we recognise is unlikely to be an important cause of medical errors. However, we have chosen to include it as it is a potentially important cause of injury in other occupations such as the military and aviation. Furthermore, there are similarities between the two disorders in terms of aetiology (i.e. circadian desynchronisation) and symptoms (i.e. insomnia and sleepiness), thus we suggest that evidence regarding the effects of interventions for jet lag will have relevance to SWD, and vice versa. To the best of our knowledge this will be the first systematic review and proposed meta-analysis aimed at assessing the effects of any intervention administered to sufferers of jet lag and SWD, on risk of injury. Although there is an existing Cochrane systematic review including trials examining the effects of melatonin for the prevention and treatment of jet lag (Herxheimer 2002), we do plan to include these studies in our review. We will however, have a primary focus on injury prevention and will be comparing the effects of melatonin with other intervention types in the context of both jet lag and SWD.
O B J E C T I V E S
To assess the effects of interventions for preventing injuries caused by impaired alertness in persons with jet lag or shift work disorder.
M E T H O D S Criteria for considering studies for this review
Types of studies
• Randomised controlled trials.
• Randomised cross-over trials.
Types of participants
Persons of any age suffering from jet lag or engaged in shift work, and who are otherwise healthy. Eligible shift workers may or may not have a formal diagnosis of SWD and could be engaged in early morning, late evening or night shift work. The onset of jet lag or SWD may be real or induced (e.g. a simulated night shift in a laboratory setting).
Types of interventions
Any intervention aimed at preventing errors caused by alertness deficits associated with jet lag or shift work disorder. Eligible interventions will incorporate:
• sedatives for facilitating sleep during episodes of insomnia;
• stimulants for promoting alertness during periods of desired wakefulness;
• interventions for facilitating adjustment of circadian rhythm through zeitgebers;
• interventions for preventing the occurrence of errors.
Anticipated interventions incorporate the following:
• Pharmaceutical stimulants (e.g. modafinil, methylphenidate, pemoline);
• Pharmaceutical sedatives (e.g. melatonin, zolpidem);
• Napping strategies (nap frequency and duration);
• Shift/flight patterns;
• Dietary interventions (e.g. energy drinks, caffeinated beverages);
• Physical activity;
• Complementary and alternative therapies;
• Environmental interventions (e.g. light levels, ambient temperature, ventilation);
• Work schedules and hours;
• Sleep detection and warning equipment (e.g. wrist worn fatigue monitors such as the Fatigue Science's SleepBand™);
• Education (e.g. sleep hygiene advice);
• Error prevention systems (e.g. alarms, computer systems).
Types of outcome measures
Primary outcomes
• Occurrence of injury.
• Occurrence of error (error as defined by the individual trial).
Secondary outcomes
• Tests of performance.
We anticipate that the included studies will use a variety of tests to measure cognitive function. We will therefore attempt to categorise the tests according to the type of cognitive construct under assessment. To do so we will refer to the classification described in Lezak 2004.
Adverse events
We also plan to collect data on the following potential adverse effects:
• Subsequent impairment of sleep architecture;
• Risk of dependence;
• Sleep inertia (the period of drowsiness and impaired performance which occurs immediately after waking).
Search methods for identification of studies
The searches will not be restricted by language or publication status.
Electronic searches
We will search the following electronic databases:
• CENTRAL;
We will use the following MEDLINE strategy adapted as appropriate to the specifications of each database. 1. exp Aerospace Medicine/ 2. exp Jet Lag Syndrome/ 3. exp Sleep Disorders, Circadian Rhythm/ 4. exp Work Schedule Tolerance/ 5. (work* adj3 schedule* adj3 tolerance*).ab,ti. 6. ((sleep-wake or time-zone) adj3 (disorder* or syndrome*)).ab,ti. 7. (circadian adj2 (dysrythmi* or disrupt* or disturb* or disorder*)).ab,ti.
8. (jet-lag* or jetlag* or shift-lag* or shiftlag).ab,ti. 9. ((shift* adj3 work*) or shiftwork* or (night* adj3 shift*) or nightshift* or (night* adj3 work*) or nightwork* or (rotat* adj3 shift*)).ab,ti. 10. exp Accidents, Aviation/pc [Prevention & Control] 11. (aviation or airtravel or (air adj1 travel) 
Searching other resources
We will search the following Internet resources:
• Computer Retrieval of Information on Scientific Projects;
• Current Controlled Trials;
• Defense Technical Information Center;
• Latin American and Caribbean Health Sciences Literature;
• Monash Accident Research Centre (www.monash.edu.au/ muarc);
• NASA Technical Reports Server;
• National Highway Traffic Safety Administration;
• National Institute for Occupational Safety and Health (www.cdc.gov/niosh);
• National Technical Information Service;
• National Transportation Library Integrated Search;
• Campbell Collaboration Social, Psychological, Educational & Criminological Trials Register;
• Swedish National Road and Transport Research Institute (VTI);
• SWOV -Institute for Road Safety Research;
These resources will be searched using keywords selected from the above MEDLINE strategy. We will also screen the electronic abstracts/proceedings of the following meetings:
• European Sleep Research Society;
• International Sleep Disorders Forum;
• World Congress of the World Association of Sleep Medicine.
In addition, we will search the reference lists of the eligible studies and any review articles for further potentially eligible articles. We will contact experts in the field as well as search the Internet using the Google (www.google.com) search engine with selected terms from the above strategy, for any further unpublished or grey literature.
Data collection and analysis

Selection of studies
Two authors will independently examine titles, abstracts, and keywords of electronic records for eligibility. We will obtain the full text of all potentially relevant reports of trials and two authors will independently assess whether each meet the pre-defined inclusion criteria. We will resolve any disagreement through discussion.
Data extraction and management
Two authors will extract data from each eligible study using a standard form that we will develop specifically for this review. We will extract data on the following:
• study design;
• participant characteristics;
• intervention characteristics;
• outcome measures;
• statistical analysis.
Assessment of risk of bias in included studies
The risk of bias in included studies will be assessed using the Cochrane Collaboration's recommended tool described in Higgins 2008. This tool assesses the following six domains:
• Sequence generation (was the allocation sequence adequately generated?);
• Allocation concealment (was allocation adequately concealed?);
• Blinding (was knowledge of the allocated intervention adequately prevented during the study?);
• Incomplete outcome data (were incomplete outcome data adequately addressed?);
• Selective outcome reporting (are reports of the study free of suggestion of selective outcome reporting?);
• Other issues (was the study apparently free of other problems that could put it at a high risk of bias?).
Risk of bias tables based on the above criteria will be completed. These will incorporate the review authors' judgement ('Yes' for low risk of bias; 'No' for high risk of bias, or 'Unclear') and description of the design, conduct or observations that underlie the judgement, for each domain in each included study.
Measures of treatment effect
We anticipate that trial results will be presented using a combination of dichotomous and continuous data. For dichotomous outcomes we plan to calculate relative risks (RR) and 95% confidence intervals (CIs) for each trial. For continuous data the weighted mean difference (WMD) and 95% CIs will be calculated when the same scale is used in a similar manner across studies. If results for continuous outcomes are reported using different scales or different versions of the same scale, we will calculate the standardised mean difference (SMD) and 95% CIs.
Unit of analysis issues
It is anticipated that we will identify a number of randomised cross-over studies which will be eligible for inclusion. If there are appropriate data we will incorporate data from all experimental periods into the analyses according to the methods described in Elbourne 2002.
Dealing with missing data
We will attempt to contact the original investigators to obtain any missing data that are required.
Assessment of heterogeneity
We will examine trial characteristics in term of participants, interventions and outcomes for evidence of clinical heterogeneity. Statistical heterogeneity will be examined by both the I-squared and chi-squared tests. The I-squared test describes the percentage of total variation across studies due to heterogeneity rather than chance. A value of 0% indicates no observed heterogeneity, and larger values show increasing heterogeneity; substantial heterogeneity is considered to exist when I-squared >50%. For the chi-squared statistic, a P value of <0.10 will be used to indicate the presence of statistically significant heterogeneity. Possible sources of heterogeneity will be assessed by subgroup analyses as described below.
Assessment of reporting biases
We will investigate the presence of reporting bias using funnel plots.
Data synthesis
If we judge that the trials are clinically and statistically homogenous, we will pool the data using the fixed-effects model.
Subgroup analysis and investigation of heterogeneity
If there are sufficient data we plan to perform the following subgroup analyses:
• Age -persons aged >60 years old versus persons aged 18 to 60 years versus children aged <18 years;
• Environment -simulated, transportation, clinical, military;
• Allocation concealment -adequate versus inadequate.
Sensitivity analysis
If there are appropriate data we will conduct the following sensitivity analyses:
• meta-analysis -comparison of fixed-effect versus randomeffects methods.
